Investigational drug · Phase 2
GZR101-80
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes (T2DM).
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GZR101-80"
First trial start
2026
Apr 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GZR101-80", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes (T2DM)
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "GZR101-80" as an intervention, largest first.
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 DiabetesPivotal-lookingNot yet recruiting
Gan & Lee Pharmaceuticals.Industry
NCT07387003 · 345 participants (planned) · Start Apr 10, 2026 · Primary completion Feb 11, 2027
Drug: GZR101-80; GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) · For: Type 2 Diabetes (T2DM)
Sites: Beijing, China
Gan & Lee Pharmaceuticals.Industry
NCT07918898 · 26 participants (planned) · Start Nov 2, 2026 · Primary completion Feb 2, 2027
Drug: GZR101 80 Injection; GZR33 Injection and 1 more · For: Healthy Participants
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes (T2DM)
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- BGM0504Phase 35 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- F027Phase 31 trial
Shandong New Time Pharmaceutical Co., LTD · Type 2 Diabetes (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.